Press Releases

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

Miami, Florida — June 13, 2025 (GLOBE NEWSWIRE) – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard® Prime EPS. CGuard Prime® was developed incorporating extensive user feedback… Read More

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Miami, Florida — June 3, 2025 (GLOBE NEWSWIRE) – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced the appointment of Michael Lawless, an industry veteran, as Chief Financial Officer, effective… Read More

InspireMD Reports First Quarter 2025 Financial Results

— Management to host investor conference call today, May 9th, at 8:30am ET— Miami, FL — May 9, 2025 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31,… Read More

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

Miami, Florida — April 30, 2025 (GLOBE NEWSWIRE) – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the Bank of America 2025 Healthcare Conference on Wednesday, May 14, 2025, at 1:15PM Eastern Time /… Read More

InspireMD to Announce First Quarter 2025 Financial Results

Miami, FL — April 25, 2025 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will… Read More

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Miami, Florida — April 8, 2025 (GLOBE NEWSWIRE) – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to 11 new non-executive employees in the aggregate amount of 299,398 shares of restricted stock… Read More

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

Miami, Florida — March 26, 2025 (GLOBE NEWSWIRE) – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 8:00AM Eastern Time /… Read More

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

— Management to host investor conference call today, March 12th, at 8:30am ET — Miami, FL — March 12, 2025 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth quarter and full… Read More

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

Miami, FL — February 26, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. In conjunction with the… Read More